NCT02016872 2025-04-30
Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients
Memorial Sloan Kettering Cancer Center
Phase NA Completed
Clinical Trials
7 trialsNCT05250895 2025-03-13
BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy
Emory University
Phase EARLY_PHASE1 Completed
NCT00606294 2023-06-28
Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT00902577 2019-04-08
MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT00559377 2016-12-30
FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01213030 2012-09-25
Clinical Evaluation of the New Hypoxia Imaging Agent HX4
Siemens Molecular Imaging
Phase 1/2 Completed
NCT00616213 2011-06-01
PR104 and G-CSF in Treating Patients With Solid Tumors
Proacta, Incorporated
Phase 1 Completed